Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 557,375,146 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 557,375,146 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 17,224,174 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 540,150,972 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 112,703,072 | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 557,375,146 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 5,532,193 | 6,303,751 | 5,346,565 | 5,942,288 | 3,455,907 | 26,580,704 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10 | 584,338,421 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2019 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2019 |
(iii) Distributable Amount for 2019 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2019 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2019: | ||||
| a From 2014....... | ||||
| b From 2015....... | ||||
| c From 2016....... | ||||
| d From 2017....... | ||||
| e From 2018....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2019 distributable amount | ||||
|
i
Carryover from 2014 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2019 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2019 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2020. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2015..... | ||||
| b Excess from 2016..... | ||||
| c Excess from 2017..... | ||||
| d Excess from 2018..... | ||||
| e Excess from 2019..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990 , PART I, LINE 1 & PART III, LINE 1 | ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| FORM 990, PART III, LINE 4 | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT DEDICATED TO UNCOVERING THE ORIGINS OF DISEASE AND LAUNCHING BOLD NEW STRATEGIES LAYING THE FOUNDATION FOR CURES. OUR INSTITUTE HAS DEEP EXPERTISE IN FUNDAMENTAL BIOLOGY AND ONE OF THE MOST COMPREHENSIVE DRUG DISCOVERY CENTERS IN THE NONPROFIT WORLD. CANCER MICROFLUID DEVICE CAPTURES CIRCULATING TUMOR CELL CLUSTERS: NEARLY 90% OF CANCER DEATHS ARE DUE TO METASTASES, WHEN TUMORS SPREAD THROUGHOUT THE BODY. TO HELP SCIENTISTS STUDY THIS PROCESS, RESEARCHERS FROM SANFORD BURNHAM PREBYS, SAN DIEGO STATE UNIVERSITY AND TUMORGEN MDX INC. CREATED A MICROFLUIDIC DEVICE THAT CAPTURES CIRCULATING CANCER CELL CLUSTERS. THE TECHNOLOGY WAS DESCRIBED IN AIP ADVANCES. DIGESTION-AIDING HERBS ALTER GUT MICROBIOME: A STUDY PUBLISHED BY SANFORD BURNHAM PREBYS AND UC SAN DIEGO SCIENTISTS IN EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE FOUND THAT DIGESTION-AIDING HERBS PROMOTED STRONG SHIFTS IN GUT BACTERIA KNOWN TO REGULATE METABOLISM. THIS INSIGHT MAY LEAD TO TREATMENTS FOR COLON CANCER, AUTOIMMUNE CONDITIONS AND MORE SERIOUS DISEASES. PREBIOTICS HELP FIGHT MELANOMA BY ACTIVATING ANTI-TUMOR IMMUNITY: TWO PREBIOTICS-NUTRIENTS THAT FEED THE FRIENDLY BACTERIA IN THE GUT-SLOWED THE GROWTH OF MELANOMA IN MICE BY BOOSTING THE IMMUNE SYSTEMS ABILITY TO FIGHT CANCER. THE STUDY, LED BY ZEEV RONAI, PH.D., PROVIDES FURTHER EVIDENCE THAT GUT MICROBES PLAY A ROLE IN SHAPING THE IMMUNE RESPONSE TO CANCER, AND SUPPORTS EFFORTS TO TARGET THE GUT MICROBIOME TO ENHANCE THE EFFICACY OF CANCER THERAPY. (CELL REPORTS) PANCREATIC CANCER BLOCKED BY DISRUPTING CELLULAR PH BALANCE: A NEW STUDY BY COSIMO COMMISSO, PH.D., ILLUSTRATES THE POTENTIAL TO TARGET CELLULAR PH-A MEASURE OF ACIDITY-AS AN APPROACH TO COMBATING PANCREATIC CANCER. BY SUPPRESSING SPECIFIC PROTEINS, THE RESEARCH TEAM WAS ABLE TO DISRUPT THE ACIDIC PH THAT CANCER CELLS USE TO SUPPORT THEIR METABOLISM. THE TEAMS NEXT STEP IS TO WORK WITH OUR DRUG DISCOVERY TEAM IN THE PREBYS CENTER TO FIND DRUGS THAT SEQUESTER ACID AND COMPROMISE PANCREATIC CELL GROWTH. (CANCER DISCOVERY) ONE-TWO PUNCH DRUG COMBINATION OFFERS HOPE FOR PANCREATIC CANCER: PANCREATIC CANCER IS ONE OF THE DEADLIEST FORMS OF CANCER-FEWER THAN 10 PERCENT OF PEOPLE REMAIN ALIVE FIVE YEARS AFTER DIAGNOSIS. ZE'EV RONAI, PH.D., IDENTIFIED A COMBINATION OF TWO FDA-APPROVED DRUGS THAT SHRANK PANCREATIC TUMORS IN MICE. THE DRUGS ARE CURRENTLY USED TO TREAT CERTAIN LEUKEMIAS AND SOLID TUMORS. THE RESEARCH SUPPORTS THE IMMEDIATE EVALUATION OF THE DRUG COMBINATION IN CLINICAL TRIALS FOR PANCREATIC CANCER. (NATURE CELL BIOLOGY) NEW SURVIVAL STRATEGY FOR OXYGEN-STARVED PANCREATIC CANCER CELLS: BY BLOCKING PANCREATIC CANCERS OXYGEN-SENSING MACHINERY-THE SAME FIELD OF RESEARCH STUDIED BY THE WINNERS OF THE 2019 NOBEL PRIZE IN MEDICINE-OUR SCIENTISTS HAVE UNCOVERED A PREVIOUSLY UNKNOWN TECHNIQUE TUMORS USE TO SPROUT BLOOD VESSELS, CALLED ANGIOGENESIS. THE DISCOVERY, PUBLISHED IN CANCER RESEARCH, COULD LEAD TO A TREATMENT THAT IS GIVEN WITH AN ANTI-ANGIOGENETIC MEDICINE AND OVERCOMES DRUG RESISTANCE. BOOSTING THE IMMUNE SYSTEM'S ABILITY TO FIGHT CANCER: CANCER IMMUNOTHERAPIES HAVE REVOLUTIONIZED THE TREATMENT OF CERTAIN CANCERS, BUT THEY DON'T WORK FOR EVERYONE. ZE'EV RONAI, PH.D., HAS SHOWN THAT THE SIAH2 PROTEIN HELPS CONTROL IMMUNE CELLS CALLED T REGULATORY CELLS, WHICH LIMIT THE EFFECTIVENESS OF IMMUNOTHERAPIES. THE RESEARCH, WHICH OFFERS A NEW WAY TO PURSUE IMMUNOTHERAPY IN CASES WHERE THE TREATMENT FAILS, WAS PUBLISHED IN NATURE COMMUNICATIONS. IMMUNOTHERAPY COMBINATION ERADICATES PEDIATRIC BRAIN CANCER: WHEN IMMUNOTHERAPY WORKS, IT CAN BE LIFE-CHANGING. BUT IT DOESN'T WORK FOR EVERYONE OR EVERY CANCER. NOW ROBERT WECHSLER-REYA, PH.D., HAS SHOWN THAT COMBINING IMMUNOTHERAPY WITH A DRUG CALLED TUMOR NECROSIS FACTOR ERADICATES A DEADLY PEDIATRIC BRAIN TUMOR IN MICE. THE DISCOVERY, PUBLISHED IN NATURE NEUROSCIENCE, IS EXPECTED TO LEAD TO A CLINICAL TRIAL FOR CHILDREN FIGHTING BRAIN CANCER. PREVENTING PANCREATIC CANCER METASTASIS BY KEEPING CELLS "SHELTERED IN PLACE": COSIMO COMMISSO, PH.D., HAS SHOWN THAT PANCREATIC CANCER METASTASIS-WHEN TUMOR CELLS GAIN THE ABILITY TO MIGRATE TO NEW PARTS OF THE BODY-CAN BE SUPPRESSED BY INHIBITING A PROTEIN THAT REGULATES CELL MOVEMENT, CALLED SLUG. THE STUDY, PUBLISHED IN THE JOURNAL OF EXPERIMENTAL MEDICINE, ALSO REVEALED TWO DRUGGABLE TARGETS THAT COULD LEAD TO TREATMENTS THAT STOP THE SPREAD OF PANCREATIC CANCER. DEGENERATIVE DISEASES ANTIMICROBIAL PROTEIN IMPLICATED IN PARKINSON'S DISEASE: AN IMMUNE SYSTEM PROTEIN THAT TYPICALLY PROTECTS THE BODY FROM PATHOGENS IS ABNORMALLY PRODUCED IN THE BRAIN DURING PARKINSON'S DISEASE, SCIENTISTS FROM SANFORD BURNHAM PREBYS REPORT. THE DISCOVERY, PUBLISHED IN FREE RADICAL BIOLOGY & MEDICINE, INDICATES THAT DEVELOPING A DRUG THAT BLOCKS THIS PROTEIN, CALLED MYELOPEROXIDASE, MAY HELP PEOPLE WITH PARKINSON'S DISEASE. PROTECTING PREMATURE BABIES FROM A COMMON BRAIN DISORDER: PREMATURE BABIES HAVE DELICATE BRAIN TISSUE THAT IS PRONE TO BLEEDING AND POST-HEMORRHAGIC HYDROCEPHALUS, A DANGEROUS CONDITION THAT LEADS TO EXCESS FLUID AND BRAIN DYSFUNCTION. JEROLD CHUN M.D., PH.D., LED A STUDY THAT OPENS NEW AVENUES TO PURSUE COMMERCIALLY AVAILABLE COMPOUNDS THAT PREVENT EXCESS FLUID FROM ACCUMULATING IN THE BRAINS OF PREMATURE INFANTS. (SCIENCE ADVANCES) |
| DEVELOPMENT, AGING AND REGENERATION | AN EARLY SIGN OF TYPE 2 DIABETES: MISFOLDED PROINSULIN: MISFOLDED PROINSULIN-A PROTEIN THE BODY NORMALLY PROCESSES INTO INSULIN-IS AN EARLY SIGN OF TYPE 2 DIABETES, ACCORDING TO A STUDY BY RANDAL KAUFMAN, PH.D. THE DISCOVERY COULD LEAD TO TESTS OR TREATMENTS THAT HELP PREVENT MORE THAN 80 MILLION AMERICANS WITH PREDIABETES FROM DEVELOPING FULL-BLOWN TYPE 2 DIABETES. THE STUDY WAS PUBLISHED IN ELIFE. MACHINE LEARNINGS NEXT FRONTIER: EPIGENETIC DRUG DISCOVERY: MACHINE LEARNINGS POWERFUL ABILITY TO DETECT PATTERNS IN COMPLEX DATA IS REVOLUTIONIZING HOW WE DRIVE CARS, DIAGNOSE DISEASE, AND NOW HOW WE DISCOVER NEW DRUGS. ALEXEY TERSKIKH, PH.D., HAS DEVELOPED A MACHINE LEARNING ALGORITHM THAT GLEANS INFORMATION FROM MICROSCOPIC DNA IMAGES-ALLOWING FOR A NEW TYPE OF HIGH-THROUGHPUT DRUG SCREENS THAT PROVIDE INSIGHTS INTO CANCER, HEART DISEASE, MENTAL ILLNESS AND OTHER HEALTH CONDITIONS. (ELIFE) A DEEP DIVE INTO CELL AGING: AN FDA-APPROVED DRUG THAT HELPED SUPPRESS THE DAMAGING EFFECTS OF CELL AGING WAS DESCRIBED IN A NEW STUDY BY PETER ADAMS, PH.D. THE RESEARCH, PERFORMED IN MICE, EXAMINED HOW AGING CELLS ENTER A SLEEP-LIKE STATE OF AGING CALLED SENESCENCE. THE STUDY IDENTIFIED A DRUG, CURRENTLY USED TO TREAT CERTAIN CANCERS, THAT TRANSFORMED SENESCENT CELLS FROM A LARGE AND FLAT FORM TO A VISUALLY YOUTHFUL CONDITION. THE TEAM PLANS TO WORK WITH THE PREBYS CENTER TO SCREEN FOR LESS TOXIC VERSIONS OF THE DRUG. (GENES & DEVELOPMENT) LONG-SOUGHT PROTEIN STRUCTURE OFFERS NEW APPROACH TO TREATING DISEASE: FRANCESCA MARASSI, PH.D., LED A COLLABORATION THAT SOLVED THE STRUCTURE OF AN ESSENTIAL BLOOD PROTEIN: VITRONECTIN. KNOWING THE PROTEIN'S STRUCTURE MAY ADVANCE OUR UNDERSTANDING OF A BROAD RANGE OF CONDITIONS INCLUDING MULTI-DRUG-RESISTANT INFECTIONS, CANCER METASTASIS, AGE-RELATED MACULAR DEGENERATION AND MORE. (SCIENCE ADVANCES) MRI PREDICTS EFFICACY OF STEM CELL THERAPY FOR BRAIN INJURY: TOOLS THAT PREDICT THE EFFICACY OF NEURAL STEM CELL THERAPY COULD INCREASE THE SUCCESS OF CLINICAL TRIALS, WHICH ARE ONGOING IN PEOPLE WITH PARKINSON'S DISEASE, SPINAL CORD INJURY AND OTHER NEUROLOGICAL CONDITIONS. EVAN SNYDER, M.D., PH.D., SUCCESSFULLY USED MRI TECHNOLOGY TO PREDICT OUTCOMES IN ANIMAL MODELS OF NEURAL INJURY. HE IS NOW PLANNING A CLINICAL TRIAL FOR BABIES BORN WITH A SPECIFIC TYPE OF BIRTH-RELATED BRAIN INJURY. (CELL REPORTS) THE SECRET TO A LONG LIFE? FOR WORMS, A CELLULAR RECYCLING PROTEIN IS KEY: NEW RESEARCH, LED BY MALENE HANSEN, PH.D., DISCOVERED THAT EXCESS LEVELS OF A SPECIFIC PROTEIN HELPS WORMS LIVE LONGER. THE PROTEIN RECOGNIZES AND DESTROYS TOXIC PROTEINS TO KEEP CELLS HEALTHY. THE FINDINGS OPEN NEW RESEARCH OPPORTUNITIES FOR AGE-RELATED CONDITIONS SUCH AS ALZHEIMER'S DISEASE, WHICH ARE OFTEN CAUSED BY THE ACCUMULATION OF MISFOLDED, HARMFUL PROTEINS. (NATURE COMMUNICATIONS) DNA SHAPE MAKES A BIG DIFFERENCE IN YOUR HEALTH: PIER LORENZO PURI, M.D., HAS USED A CUTTING-EDGE GENOMIC TECHNOLOGY TO SHOW THAT MYOD-A MASTER REGULATOR OF MUSCLE DEVELOPMENT-CAN ALTER THE GENOME'S ARCHITECTURE AND DETERMINE IF DNA MUTATIONS ARE EXPRESSED OR HIDDEN. THE STUDY, PUBLISHED IN MOLECULAR CELL, HELPS EXPLAIN WHY PATIENTS WITH THE SAME MUTATION CAN HAVE DIFFERENT DISEASE PROGRESSION AND SYMPTOMS. RESEARCH UNCOVERS GENETIC MUTATIONS LINKED TO AUTISM SPECTRUM DISORDER: SCIENTISTS AT SANFORD BURNHAM PREBYS AND RADBOUD UNIVERSITY MEDICAL CENTER IN THE NETHERLANDS HAVE IDENTIFIED MUTATIONS IN A GENE CALLED CNOT1 THAT AFFECT BRAIN DEVELOPMENT AND IMPAIR MEMORY AND LEARNING. THE RESEARCH, PUBLISHED IN THE AMERICAN JOURNAL OF HUMAN GENETICS, ALSO REVEALED THAT CNOT1 INTERACTS WITH SEVERAL KNOWN AUTISM SPECTRUM DISORDER GENES, OPENING NEW RESEARCH AVENUES FOR THE CONDITION. POTENTIAL DRUG TARGET FOR TYPE 2 DIABETES REVEALED BY MAPPING PROINSULINS "SOCIAL NETWORK": FOR THE FIRST TIME, SANFORD BURNHAM PREBYS SCIENTISTS HAVE MAPPED THE VAST NETWORK OF PROTEINS THAT INTERACT WITH PROINSULIN, THE PROTEIN THE BODY NORMALLY PROCESSES INTO INSULIN. THE STUDY, PUBLISHED IN DIABETES, REVEALED ONE PROTEIN-CALLED PRDX4-THAT MAY BE ESSENTIAL FOR PROINSULIN FOLDING AND INSULIN PRODUCTION. THE RESEARCH SUGGESTS THAT BOOSTING PRDX4 LEVELS MAY IMPROVE THE HEALTH OF PEOPLE WITH DIABETES. HUMAN GENETICS ADVANCING STEM CELL THERAPIES FOR BRAIN INJURY: EVAN SNYDER, M.D., PH.D., TEAMED UP WITH SCIENTISTS AT LOMA LINDA UNIVERSITY HEALTH TO DEMONSTRATE THE PROMISE OF USING MAGNETIC RESONANCE IMAGING (MRI) TO HELP PREDICT THE EFFICACY OF STEM CELL TREATMENTS FOR NEUROLOGICAL DISORDERS. THE RESEARCHERS ARE PLANNING A CLINICAL TRIAL FOR NEWBORNS WHO EXPERIENCE A BIRTH-RELATED BRAIN INJURY. THE STUDY WAS PUBLISHED IN CELL REPORTS. FIRST SUPERCENTENARIAN IPSCS CREATED: EVAN SNYDER, M.D., PH.D., HAS SUCCESSFULLY REPROGRAMMED CELLS FROM A 114-YEAR-OLD WOMAN INTO INDUCED PLURIPOTENT STEM CELLS (IPSCS). NOW, STUDIES CAN BEGIN TO REVEAL THE "SECRET SAUCE" OF SUPERCENTENARIANS-WHO LIVE REMARKABLY LONG AND HEALTHY LIVES. THE STUDY WAS PUBLISHED IN BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. NEW TEST FOR RARE DISEASE IDENTIFIES CHILDREN WHO MAY BENEFIT FROM SIMPLE SUPPLEMENT: HUDSON FREEZE, PH.D., TEAMED WITH SCIENTISTS AT THE CENTRO DE BIOLOGA MOLECULAR SEVERO OCHOA IN SPAIN TO CREATE A TEST THAT DETERMINES WHICH CHILDREN WITH CAD DEFICIENCY-A RARE METABOLIC DISEASE-ARE LIKELY TO BENEFIT FROM RECEIVING URIDINE, A NUTRITIONAL SUPPLEMENT THAT CAN DRAMATICALLY IMPROVE THE LIVES OF CHILDREN WITH THE CONDITION. THE STUDY WAS PUBLISHED IN GENETICS IN MEDICINE. IMMUNITY AND PATHOGENESIS FOUR DRUGS HOLD NEAR-TERM PROMISE TO FIGHT COVID-19: SUMIT CHANDA, PH.D., LED AN INTERNATIONAL COLLABORATION THAT SCREENED MORE THAN 12,000 EXISTING DRUGS FOR ACTIVITY AGAINST SARS-COV-2, THE VIRUS THAT CAUSES COVID-19. FOUR OF THE DRUGS WERE ABLE TO STOP THE VIRUS FROM REPLICATING AT DOSES LIKELY TO BE EFFECTIVE AND TOLERABLE IN HUMANS. THE RESEARCH INCREASES THE NUMBER OF "SHOTS ON GOAL" FOR A POTENTIAL TREATMENT AND COULD REACH PATIENTS FASTER THAN DRUGS CREATED FROM SCRATCH. (BIORXIV) NEW DRUG CANDIDATE REAWAKENS SLEEPING HIV IN HOPES OF A CURE: SANFORD BURNHAM PREBYS SCIENTISTS HAVE DESIGNED A NEXT-GENERATION DRUG CALLED CIAPAVIR THAT IS EFFECTIVE AT REACTIVATING DORMANT HUMAN IMMUNODEFICIENCY VIRUS (HIV). THE RESEARCH, PUBLISHED IN CELL REPORTS MEDICINE, AIMS TO CREATE A FUNCTIONAL HIV CURE USING A "SHOCK AND KILL" APPROACH THAT FIRST ACTIVATES AND THEN ELIMINATES ALL POCKETS OF DORMANT HIV. |
| FORM 990, PART VI, LINE 11B | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, LINE 12C | DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTERESTS THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. IN ADDITION, EACH YEAR NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTES CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS/MAY EXIST AND WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICIPATING IN THE BOARDS DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. |
| FORM 990, PART VI, LINES 15A & 15B | PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON AUGUST 26, 2020 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CAO/CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) PROGRAM DIRECTOR/PROFESSOR 7) CANCER CENTER DIRECTOR/PROFESSOR 8) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR |
| FORM 990, PART VI, LINE 19 | PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| Software ID: | |
| Software Version: |